Walvax Biotechnology Co., Ltd. (SHE:300142)

Market Cap	19.56B
Revenue (ttm)	2.40B
Net Income (ttm)	49.24M
Shares Out	1.60B
EPS (ttm)	0.03
PE Ratio	397.20
Forward PE	56.88
Dividend	0.01 (0.08%)
Ex-Dividend Date	May 28, 2025

Volume	29,563,099
Average Volume	26,465,980
Open	12.36
Previous Close	12.23
Day's Range	11.97 - 12.36
52-Week Range	9.70 - 17.24
Beta	0.45
RSI	62.19
Earnings Date	Oct 29, 2025

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 2,388
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300142

Financial Performance

In 2024, Walvax Biotechnology's revenue was 2.82 billion, a decrease of -31.41% compared to the previous year's 4.11 billion. Earnings were 142.16 million, a decrease of -66.10%.